ArticleDrug design, development and therapy2019

AR-42: A Pan-HDAC Inhibitor with Antitumor and Antiangiogenic Activities in Esophageal Squamous Cell Carcinoma.

Yuxuan Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.